Summit Wealth Partners LLC Purchases 2,771 Shares of Johnson & Johnson $JNJ

Summit Wealth Partners LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 25.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,513 shares of the company’s stock after acquiring an additional 2,771 shares during the period. Summit Wealth Partners LLC’s holdings in Johnson & Johnson were worth $3,303,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Auto Owners Insurance Co boosted its position in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after buying an additional 69,108,368 shares during the period. Norges Bank purchased a new position in shares of Johnson & Johnson in the fourth quarter worth about $6,924,523,000. Capital World Investors bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $2,005,942,000. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after acquiring an additional 3,731,074 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in Johnson & Johnson by 41.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,423,886 shares of the company’s stock worth $2,571,124,000 after acquiring an additional 3,655,754 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $241.22 on Thursday. The company has a 50-day simple moving average of $230.50 and a two-hundred day simple moving average of $228.94. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The firm has a market capitalization of $580.68 billion, a PE ratio of 27.89, a price-to-earnings-growth ratio of 2.34 and a beta of 0.26. Johnson & Johnson has a one year low of $150.73 and a one year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the prior year, the business earned $2.77 EPS. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.2%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson is benefiting as investors move out of higher-volatility tech and into lower-risk dividend names, which has helped lift the stock. Why Johnson & Johnson, Altria, Verizon, and Other Safe Dividend Stocks Climbed Today
• Positive Sentiment: New articles are again spotlighting JNJ as a quality dividend aristocrat, keeping the stock on income investors’ radar and reinforcing its defensive appeal. 3 Quality Dividend Aristocrats to Buy in June
• Positive Sentiment: Seeking Alpha upgraded the stock, arguing that not every dollar needs to chase the AI boom, which supports the view that JNJ remains attractive as a steadier alternative. Johnson & Johnson: Not Every Dollar Needs To Chase The AI Boom (Upgrade)
• Positive Sentiment: Coverage also highlighted recent wins in oncology, rare disease, and MedTech, including strong clinical data and product availability updates that could improve the company’s growth outlook. How Oncology, Rare Disease and MedTech Wins At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Neutral Sentiment: Additional commentary framed JNJ as a retirement-income and defensive-anchor stock, which is supportive for sentiment but does not appear to be driven by a new catalyst. Johnson & Johnson Stock Performance

Analysts Set New Price Targets

Several analysts have weighed in on the company. Guggenheim boosted their price objective on Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Citigroup raised their target price on shares of Johnson & Johnson from $274.00 to $285.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a report on Wednesday, April 15th. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Finally, Argus boosted their price objective on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Twenty equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.04.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.